The association between C-reactive protein and the likelihood of progression to joint replacement in people with rheumatoid arthritis: a retrospective observational study by Poole, Chris D et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Musculoskeletal Disorders
Open Access Research article
The association between C-reactive protein and the likelihood of 
progression to joint replacement in people with rheumatoid 
arthritis: a retrospective observational study
Chris D Poole1, Pete Conway2, Alan Reynolds3 and Craig J Currie*4,5
Address: 1360° Research Limited, Penarth, UK, 2Health Economics, Wyeth Europa Limited, Maidenhead, UK, 3Scientific Affairs, Wyeth 
Pharmaceuticals, Maidenhead, UK, 4Department of Medicine, School of Medicine, Cardiff University, Cardiff UK and 5Health Evaluation 
Associates, The Pharma Research Centre, Cardiff MediCentre, Cardiff CF14 4UJ, UK
Email: Chris D Poole - drchrispoole@googlemail.com; Pete Conway - conwaypa@wyeth.com; Alan Reynolds - reynola@wyeth.com; 
Craig J Currie* - currie@cardiff.ac.uk
* Corresponding author    
Abstract
Background: This study sought to evaluate the association between systemic inflammation as
measured by C-reactive protein and total joint replacement and the association between change in
CRP status (low, ≤ 10 mg/L and high, >10 mg/L) measured over one year and total joint
replacement in patients diagnosed with rheumatoid arthritis.
Methods: A cohort of patients was selected from The Health Improvement Network (THIN)
dataset of anonymised patient-level data from UK general practice with a confirmed chronic
rheumatic diagnosis. Surgery-free survival was evaluated using Cox proportional hazards regression
models (CPHM).
Results: 2,421 cases had at least one CRP measurement of which 125 cases (5.2%) had at least one
major joint replacement. In CPHM, each additional unit increase in log mean CRP (range 1 to 6)
was associated with a hazard ratio (HR) for major orthopaedic surgery of 1.36 (95% CI 1.10 to 1.67;
p = 0.004), after controlling for age at first rheumatoid presentation and average body mass index
over the same observation period. Repeated CRP observations around one year apart were
recorded in 1,314 subjects. After controlling for confounding factors, in cases whose CRP remained
high (>10 mg/L), the HR for joint replacement increased more than two-fold (p = 0.040) relative
to cases whose CRP remained low. In patients whose CRP increased from low to high, the HR was
1.86 compared to those who remained in a low state (p = 0.217). By comparison, among those
subjects whose CRP was reduced from a high to low state, the hazard ratio was more than halved
(1.46) from to those who remained high (p = 0.441). Although underpowered, the trend evident
from CRP change corroborates the association of TJR progression with mean CRP.
Conclusion: CRP level predicts progression to major joint replacement after standardisation for
relevant risk factors as did change in CRP status between low and high states observed over one
year.
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Background
Rheumatoid arthritis (RA) is a chronic illness character-
ised by inflammation of the synovial tissue in joints
which can lead to joint destruction. Despite early and
more aggressive treatment policies aimed at limiting the
disease pathology rather than just controlling symptoms,
progressive destruction of joints continues in a subgroup
of patients who eventually require surgery. The ERAS
Group inception cohort provides the most accurate data
for the UK; in the first five years of observation seventeen
percent of RA patients treated with conventional therapy
required orthopaedic surgical intervention, 41% of whom
underwent major joint replacement [1]. This is consistent
with other observational studies [2], which also showed
that by 10 years 20% of RA patients require surgery [3],
and within 20 years a quarter of all patients will have
undergone total joint arthroplasty (TJA) [4].
Although a significant long-term outcome in RA, joint
replacement surgery is currently excluded from accepted
economic models evaluating the cost-effectiveness of dis-
ease modifying anti-rheumatic drugs (DMARD) because
of the absence of data on the effects of DMARDs on joint
replacement rates [5]. The long-term impact of tumour
necrosis factor alpha (TNF-α) inhibitors on joint failure
and the likelihood of orthopaedic surgery cannot be dem-
onstrated directly at present because the agents are still rel-
atively new. Surrogate end-points such as radiographic
change suggest potentially important benefits [6], and
potentially a reduced demand for surgery, but the clinical
relevance of reported radiographic changes is debated [7].
Surrogate markers of inflammation measured by labora-
tory assay such as erythrocyte sedimentation rate (ESR)
and C-reactive protein are central in the evaluation of dis-
ease progression and response to therapeutic intervention
[8-10]. Although the baseline prognostic value of these
inflammatory markers for joint replacement has been
assessed [1,11], few studies have looked at their predictive
value when assessed over the lifetime of the disease. Fur-
thermore no study appears to have examined the relation-
ship between longitudinal change in CRP and
orthopaedic prognosis, as has been true for evaluation of
the effect of such changes upon the risk of cardiovascular
disease in other patient groups [12].
In this study, we sought to examine effect of both average
CRP and CRP change on progression to total joint replace-
ment using routine laboratory data recorded in general
practice among patients diagnosed with rheumatoid
arthritis.
Methods
Data analysed in this study were derived from routine gen-
eral practice in the UK. These data were sourced from a
proprietary health data resource, The Health Improve-
ment Network (THIN) [13], a competitor to the General
Practice Research Database (GPRD) [14], a widely recog-
nised source of UK GP data. THIN was selected since it
had greater patient numbers matching the initial selection
criteria.
THIN data are collected in a non-interventional way from
the daily record keeping of primary care physicians in the
UK. The records are anonymised at the collection stage so
that researchers have access to an encrypted identifier for
the physician's office and the patient. They provide a lon-
gitudinal medical record for each patient. Currently, the
dataset consists of contributions from over 300 practices
and data from approximately five million patients of
whom over 2.3 million are actively registered with the
practices and can be prospectively followed. The remain-
ing patients have historical data but have either left the
practice or died. There are nearly 30 million patient years
of computerised data in THIN. On average, patients have
full data for six years and may have up to 15 years of
observations. Data from THIN consist of four categories
that detail the following: 1) subject demographic details;
2) medical history (diagnoses); 3) test results and addi-
tion health-related data such as smoking status; and 4)
drug treatments. Ethical approval was granted by the
Cambridge MREC.
Patient selection
Data were extracted for patients with a diagnosis for rheu-
matoid arthritis (RA) recorded at least twice on two differ-
ent dates. A marker of 'newly diagnosed' was assigned if
the patient had less than six months case history prior to
first RA diagnostic code.
Of these patients, the first rheumatoid presentation
(index event) was determined from the first of the follow-
ing three events: either 1) occurrence of three consecutive
monthly prescriptions for a non-steroidal anti-inflamma-
tory drug (NSAID); or 2) recorded rheumatology referral,
consultation or screening; or 3) an RA diagnosis. Cases
were further selected by presence of at least one valid CRP
measurement between the index date (the date of the
index event) and study endpoint.
Finally, to be assured of following cases from their first
rheumatoid presentation, a minimum wash-in period of
six months between the date of first contact with the data-
base and the index date was applied.
Endpoint determination
The observational endpoint was the first recorded date of
a major orthopaedic intervention which included hip,
knee, shoulder, elbow joint replacement or cervical spine
fusion, in common with the Early Rheumatoid ArthritisBMC Musculoskeletal Disorders 2008, 9:146 http://www.biomedcentral.com/1471-2474/9/146
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Study Group [1]. Those who did not progress to TJR were
censored at the date of last contact or death.
Laboratory data
The key marker in this investigation, serum CRP concen-
tration, is reported as provided in THIN. CRP observa-
tions were utilised only if they had a value >0 in order to
be sure that this was a true observation and not a null
value attributed 0 (zero) systematically or at data entry.
Recorded total cholesterol (TC) observations were simi-
larly treated. Mean CRP was calculated for all valid obser-
vations between index and study endpoint, as was mean
body mass index (BMI) and mean blood pressure (systolic
and diastolic).
Cases where CRP change was recorded were included
where at least two observations were recorded approxi-
mately one year apart (± 90 days in order to recruit suffi-
cient cases). Given high intra-individual variability for
CRP [15,16], baseline CRP status was calculated as the
average of all observations within 90 days of the first CRP
observation. Similarly, the follow-up CRP level was
defined as the mean of values occurring within a further
90 day of the second (1 year) observation. It was not pos-
sible to determine whether the assays were of high sensi-
tivity therefore decided to categorize CRP level according
to the scientific statement recently issued by the American
Heart Association and Centers for Disease Control and
Prevention [17] a method used previously in large epide-
miological studies [18]. A low level of CRP was defined as
10 mg/L or less whilst levels in excess of 10 mg/L were
defined as high based on published population norms.
CRP change was then defined for the period as low → low
(LL), low → high (LH), high → low (HL), and high →
high (HH). Classification by the method used in a recent
study of hospital laboratory data [19] was not feasible in
this instance as too few cases in the CRP change subgroup
met the AHA criteria for 'normal' CRP (≤ 3 mg/L). Any
case in the CRP change subgroup who had a recorded
diagnosis of an acute ischaemic event during their CRP
observation period (± 30 days) was excluded from analy-
sis.
Statistical methods
Survival was evaluated using Cox proportional hazards
regression analysis (CPHM), using SPSS® v15, SPSS Inc,
Chicago. Independent covariates of survival were tested
using a manual forward inclusion method with a thresh-
old significance of p = 0.05 as the criterion for inclusion
in the final models. Time to event was measured from the
date of the last reported CRP observation. Surviving cases
were right-censored by their last known contact date.
Results
Among 7,121 cases with 'newly-diagnosed' rheumatoid
arthritis, 3,576 cases had at least one valid CRP measure-
ment of which 2,421 (34% of the initial sample) had a 6-
month run-in prior to their first rheumatoid presentation.
There were 125 major joint replacements (5.2%) in this
cohort, the majority (95.2%) being of the hip or knee
(39.2% and 56.0% respectively). The median time from
RA diagnosis to TJR was 49 months (IQR: 25 to 104). In
total there were 24,023 CRP observations from the 2,421
cases, 76% of whom had more than one CRP measure-
ment. The median number of CRP observations per case
was 4 (IQR: 2 to 13) and the median time to event (TJR or
censor) was 117 months (IQR: 71 to 161). There was no
statistically significant difference in the frequency of CRP
testing between those who progressed to TJR and censored
cases (p = 0.122).
Cases progressing to TJR were significantly older at first
presentation than non-TJR cases (59.5 vs. 51.4 years; p <
0.001; had a higher average BMI prior to major surgery
(28.1 kg/m2 vs. 26.9 kg/m2; p = 0.051); had higher average
systolic blood pressure (145 mmHg vs. 137 mmHg; p <
0.001); and had higher mean CRP prior to surgery (19.16
mmol/L vs. 12 mmol/L; p < 0.001; Table 1).
Cases from the initial sample with no recorded CRP
results were an historically older cohort. Their median
year of first RA diagnosis was 1997 (IQR: 1993 to 2001)
whilst for those with CRP measurements median year of
diagnosis was 2001 (IQR: 1997 to 2003, p < 0.001).
Mean CRP measurement
CPHM showed each unit increase in log mean CRP was
associated with a 36% increase in the HR for TJR (95% CI
10% to 67%; Table 2) after controlling for age at index,
and mean BMI. Gender, mean total cholesterol, mean
SBP, smoking status, prior cardiovascular morbidity, and
number of visits to the GP in the year prior to CRP meas-
urement were not significant covariates in the presence of
those factors remaining in the model. Survival curves for
each thirtile of mean CRP (adjusted for index age and
mean BMI) are shown (Figure 1).
CRP change
Repeated CRP observations at one year were available for
1,287 subjects, of whom 54 experienced at least one
major joint replacement. The median number of tests in
the quarter following first-ever CRP observation was 1
(IQR: 1 to 2). In the follow-up period (9 to 15 months
after first CRP) the median number of CRP observations
was 2 (IQR: 1 to 4).
In a CPHM model of all-cause mortality controlling for
age at index, the hazard of joint replacement showed aBMC Musculoskeletal Disorders 2008, 9:146 http://www.biomedcentral.com/1471-2474/9/146
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trend between CRP change categories consistent with the
finding for mean CRP (Table 3 & Figure 2). Compared to
stable low-CRP cases, the hazard ratio of TJR among per-
sistently high-CRP was approximately doubled (HR 2.19
[95%CI 1.04 to 4.64; p = 0.040]). Among those whose
CRP increased from low to high, the hazard ratio was 1.86
(95%CI 0.69 to 5.01) but this observation did not reach
threshold significance (p = 0.217). The hazard ratio for
those whose CRP returned from an elevated to a low state,
showed no statistically significant difference from the sta-
ble low-CRP reference group (HR 1.46 [95%CI 0.56 to
3.78; p = 0.441]).
The time dependency of CRP was tested to ensure compli-
ance with CPHM assumptions. First CRP was not corre-
lated with time from index (rPearson = -0.032, p = 0.121)
and mean CRP was not correlated with time from first
CRP to last CRP (rPearson = -0.042, p = 0.072).
Discussion
This is the first study to demonstrate that increased mean
CRP observed throughout the disease process is associated
with accelerated progression to total joint replacement for
patients with rheumatoid arthritis. Further, the change in
serum CRP between low and high levels also appears cor-
related with progression to major surgical endpoints, sug-
gesting that the risk is modifiable. An absence of statistical
significance in these last findings would have been
expected from the diminished number of events in this
reduced cohort. The concordance of results using both a
statistical classification (thirtiles of mean CRP) and an a
priori population-based classification (for CRP change)
serves to strengthen the findings.
In this cohort the median time from diagnosis to joint
replacement was 49 months, correspondent to the upper
end of centres contributing to the UK-based ERAS study
[1] in which the overall median time from baseline was 36
months. This figure does differ from other reported esti-
mates which put median time at 7.0 [20] years (US-based
outpatient study) for any total joint arthroplasty and
around 14 years for total replacement of large joints
(Finnish outpatient study) [21]. It is likely in this primary
care dataset that case ascertainment is underestimated.
The current data span a 20 year period in which significant
changes in the management of RA has occurred which
would reasonably have been expected to modify practice
primary care. The ERAS study represents an assessment of
Table 1: Subject characteristics by study outcome
All subjects No joint replacement TJR p
number (%) 2,421 2,296 94.4% 125 5.2%
% male 26.0% 26.0% 26.4% 0.917
Mean age at index (SD) 51.9 15.0 51.4 15.0 59.4 11.5 <0.000
Prior ischaemic disease (%) 10.1 10.0 10.4 0.878
Median GP visits yr prior (IQR) 10 (6–18) 10 (6–18) 10.5 (6–18) 0.781
Mean BMI before CRP (SD) 26.9 5.6 26.9 5.6 28.1 6.3 0.051
Mean SBP before CRP (SD) 137.4 16.6 137.0 16.5 145.1 16.1 <0.000
Mean TC before CRP (SD) 5.35 1.00 5.35 1.00 5.45 0.93 0.388
Ever smoked (%) 38.4 38.8 31.5 0.107
Ln mean CRP (SD) 2.51 1.01 2.49 1.00 2.95 0.98 <0.000
Number of deaths (%) 194 8.0 185 8.1 9 7.2 0.866
Index – 1st rheumatoid event; TJR – major orthopaedic intervention (ERAS definition) – standard deviation; IQR – inter-quartile range;
BMI – body mass index (kg/m2); SBP – systolic blood pressure (mmHg); TC – total serum cholesterol (mmol/L); Ln – natural logarithm.
Table 2: Cox proportional hazards model for first total joint replacement (n = 1,885; 3.6% events)
Variables in the Equation β SE p HR 95% CI for HR
Lower Upper
Age at index 0.044 0.009 0.000 1.04 1.03 1.06
Ln mean CRP 0.307 0.106 0.004 1.36 1.10 1.67
Mean BMI 0.041 0.018 0.022 1.04 1.01 1.08
Covariates not reaching threshold significance: gender; mean total cholesterol; mean BP; smoking history; cardiovascular morbidity; prior year GP 
attendance.
β – parameter estimate; SE – standard error of β;p – statistical significance; HR – hazard ratio;
CI – confidence interval.BMC Musculoskeletal Disorders 2008, 9:146 http://www.biomedcentral.com/1471-2474/9/146
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relatively recent rheumatology best practice. Thus, hazard
ratios are likely to be reliable; however absolute risk is
likely to be underestimated because of the probability of
under-reporting by the GPs. This under-reporting is
unlikely to be systematic. These purely observational pri-
mary care cases will incorporate additional delays such as
referral and patient non-compliance. A further source of
underestimation comes from our inclusion of non-survi-
vors in the censored cohort. A decision was taken to
include these cases to provide a more relevant estimate
including other outcomes from RA, including mortality.
Despite their limitations, these findings do illustrate the
association between mean CRP change over the course of
Surgery-free survival by mean CRP thirtile (low [<8.03 mmol/L], intermediate [8.03 to 18.32 mmol/L], and high [>18.32 mmol/ L]) standardised for age, and average BMI Figure 1
Surgery-free survival by mean CRP thirtile (low [<8.03 mmol/L], intermediate [8.03 to 18.32 mmol/L], and 
high [>18.32 mmol/L]) standardised for age, and average BMI.
Table 3: Cox proportional hazards model for first total joint replacement after one-year CRP observation (n = 1,230; 4.2% events)
Variables in the Equation B SE p HR 95% CI for HR
Lower Upper
Age at index 0.061 0.012 0.000 1.06 1.04 1.09
1-year CRP change (cf. Low-Low)0 . 2 0 3
Low to High 0.623 0.504 0.217 1.86 0.69 5.01
High to Low 0.375 0.487 0.441 1.46 0.56 3.78
High-High 0.786 0.382 0.040 2.19 1.04 4.64
Covariates not reaching threshold significance: gender; time to 1st CRP observation.
Low CRP defined as ≤ 10 mmol/L; High CRP defined as >10 mmol/LBMC Musculoskeletal Disorders 2008, 9:146 http://www.biomedcentral.com/1471-2474/9/146
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the disease process and subsequent need for joint replace-
ment. As such CRP could reasonably be used as a surro-
gate marker in modelling endpoints for the comparison of
disease modifying anti-rheumatic drug treatments where
no long-term outcome data exists. Given that currently
accepted cost-effectiveness models for DMARDs do not
include joint replacement as an endpoint gives added
weight to the utility of these findings. An analogous situ-
ation would be the exclusion of microvascular and mac-
rovascular endpoints from the current economic
modelling of new hypoglycaemic agents. In common
with the TNF-α blockers, neither the clinical trials pro-
gramme nor extensive post-marketing surveillance for
hypoglycaemic treatment could reasonably be expected to
show a direct reduction in these long-term endpoints yet
improvement in HbA1c, is universally accepted a surro-
gate for disease control [22].
As a marker of disease status, CRP has limitations. CRP
levels change more readily in response to other inflamma-
tory stimuli such as minor infections and surgery. Erythro-
cyte sedimentation rate (ESR) could have provided a more
stable surrogate for disease status but results were not suf-
ficiently available in this register study. Counts of swollen
and tender joints presented during follow-up would also
have provided a more accurate picture of disease status
but are poorly recorded in primary care data and may have
been difficult to quantify over time. Other direct assays of
type I collagen destruction such as ICTP have shown good
prognostic ability for TJR [23] but are not routinely
recorded.
The current observation that change in CRP modifies the
risk of joint progression will also be of interest to those
assessing disease prognosis in rheumatoid disease. As this
Surgery-free survival by 1-year CRP change status standardised for age (CRP status: Low, ≤ 10 mmol/L; High, >10 mmol/L) Figure 2
Surgery-free survival by 1-year CRP change status standardised for age (CRP status: Low, ≤ 10 mmol/L; High, 
>10 mmol/L).BMC Musculoskeletal Disorders 2008, 9:146 http://www.biomedcentral.com/1471-2474/9/146
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study could only demonstrate association and not causa-
tion, further studies will consider which therapeutic inter-
ventions control inflammation most effectively, and
whether direct benefit in limiting progression to joint
replacement can be characterised.
Conclusion
Therapeutic practice is evolving in rheumatoid arthritis
with the introduction of biologic agents which provide
rapid, profound and sustained suppression of disease
activity in correspondence with a marked reduction in
CRP levels [24]. In 2007, primary care prescriptions for
adalimumab and etanercept accounted for 0.4% of all
DMARDs [25], making their current presence on practice
databases vanishingly small. Their long-term benefit on
relevant endpoints such as TJA cannot be established until
a substantial body of practice data has accrued. Until then
surrogates of the disease process including inflammatory
markers can give an indication of the likely prognosis
when these agents are used. The present analysis suggests
that one of these surrogates, CRP, has value in the progno-
sis of TJA.
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